IL55774A
(en)
*
|
1977-10-28 |
1982-04-30 |
Sparamedica Ag |
Pharmaceutical compositions containing urea derivatives,certain such novel derivatives and their manufacture
|
MC1220A1
(fr)
*
|
1977-10-28 |
1979-07-20 |
Hoffmann La Roche |
Nouveaux derives d'imidazolidine
|
FI801184A
(fi)
*
|
1979-04-24 |
1980-10-25 |
Hoffmann La Roche |
Foerfarande foer framstaellning av imidazolidinderivat
|
US4760053A
(en)
*
|
1984-08-02 |
1988-07-26 |
Fernand Labrie |
Combination therapy for selected sex steroid dependent cancers
|
US4666885A
(en)
*
|
1985-02-08 |
1987-05-19 |
Fernand Labrie |
Combination therapy for treatment of female breast cancer
|
US4775660A
(en)
*
|
1984-08-02 |
1988-10-04 |
Fernand Labrie |
Treatment of breast cancer by combination therapy
|
AU594309B2
(en)
*
|
1984-08-02 |
1990-03-08 |
Fernand Labrie |
Pharmaceutical composition for combination therapy of hormonedependent cancers
|
IT1214735B
(it)
*
|
1986-11-04 |
1990-01-18 |
Roussel Maestretti Spa |
Impiego di 1-(3'-trifluorometil 4'nitrofenil) 4,4-dimetilimidazolin2,5-dione per il trattamento di cancri ormonodipendenti diverso da quello della prostata
|
US5084472A
(en)
*
|
1986-11-04 |
1992-01-28 |
Roussel |
Application of 1-(3'-trifluoromethyl-4'-nitrophenyl)-4,4'-dimethylimidazoline 2,5-dione in the treatment of hormone-dependent cancers other than that of the prostate
|
FR2619381B1
(fr)
*
|
1987-08-13 |
1989-12-08 |
Roussel Uclaf |
Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation
|
US4895715A
(en)
*
|
1988-04-14 |
1990-01-23 |
Schering Corporation |
Method of treating gynecomastia
|
FR2656302B1
(fr)
*
|
1989-12-22 |
1992-05-07 |
Roussel Uclaf |
Nouveau procede de preparation de l'anandron et derives de l'anandron.
|
FR2671348B1
(fr)
*
|
1991-01-09 |
1993-03-26 |
Roussel Uclaf |
Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
|
FR2693461B1
(fr)
*
|
1992-07-08 |
1994-09-02 |
Roussel Uclaf |
Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
|
US5411981A
(en)
*
|
1991-01-09 |
1995-05-02 |
Roussel Uclaf |
Phenylimidazolidines having antiandrogenic activity
|
USRE35956E
(en)
*
|
1991-01-09 |
1998-11-10 |
Roussel Uclaf |
Phenylimidazolidines having antiandrogenic activity
|
FR2685328B1
(fr)
*
|
1991-12-20 |
1995-12-01 |
Rhone Poulenc Agrochimie |
Derives de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
|
FR2706456B1
(fr)
*
|
1993-06-18 |
1996-06-28 |
Rhone Poulenc Agrochimie |
Dérivés optiquement actifs de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
|
US6002016A
(en)
*
|
1991-12-20 |
1999-12-14 |
Rhone-Poulenc Agrochimie |
Fungicidal 2-imidazolin-5-ones and 2-imidazoline-5-thiones
|
FR2694290B1
(fr)
*
|
1992-07-08 |
1994-09-02 |
Roussel Uclaf |
Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
|
US6008370A
(en)
*
|
1992-11-25 |
1999-12-28 |
Rhone-Poulenc Agrochimie |
Fungicidal-2-alkoxy/haloalkoxy-1-(mono- or disubstituted)amino-4,4-disubstituted-2-imidazolin-5-ones
|
FR2724169B1
(fr)
*
|
1994-09-06 |
1997-01-03 |
Roussel Uclaf |
Nouvelles phenylimidazolidines eventuellement substituees, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
|
FR2715402B1
(fr)
*
|
1994-01-05 |
1996-10-04 |
Roussel Uclaf |
Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
|
TW521073B
(en)
*
|
1994-01-05 |
2003-02-21 |
Hoechst Marion Roussel Inc |
New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
|
FR2725206B1
(fr)
*
|
1994-09-29 |
1996-12-06 |
Roussel Uclaf |
Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
|
US5656651A
(en)
*
|
1995-06-16 |
1997-08-12 |
Biophysica Inc. |
Androgenic directed compositions
|
US6566372B1
(en)
|
1999-08-27 |
2003-05-20 |
Ligand Pharmaceuticals Incorporated |
Bicyclic androgen and progesterone receptor modulator compounds and methods
|
CA2413417A1
(en)
*
|
2000-06-28 |
2002-01-03 |
Bristol-Myers Squibb Company |
Selective androgen receptor modulators and methods for their identification, design and use
|
US7001911B2
(en)
*
|
2000-06-28 |
2006-02-21 |
Bristol-Myers Squibb Company |
Fused cyclic modulators of nuclear hormone receptor function
|
US20040077605A1
(en)
*
|
2001-06-20 |
2004-04-22 |
Salvati Mark E. |
Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
|
EP1854798A3
(en)
|
2000-09-19 |
2007-11-28 |
Bristol-Myers Squibb Company |
Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
|
US6953679B2
(en)
|
2000-09-19 |
2005-10-11 |
Bristol-Myers Squibb Company |
Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
|
US20040087548A1
(en)
|
2001-02-27 |
2004-05-06 |
Salvati Mark E. |
Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
|
AU2002322493A1
(en)
*
|
2001-07-10 |
2003-01-29 |
Ams Research Corporation |
Surgical kit for treating prostate tissue
|
PL206962B1
(pl)
*
|
2001-12-19 |
2010-10-29 |
Bristol Myers Squibb Co |
Związek heterocykliczny o budowie skondensowanej
|
US7354933B2
(en)
*
|
2003-01-31 |
2008-04-08 |
Aventis Pharma Sa |
Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
|
FR2850652B1
(fr)
*
|
2003-01-31 |
2008-05-30 |
Aventis Pharma Sa |
Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
|
AU2004266160A1
(en)
*
|
2003-08-22 |
2005-03-03 |
Ligand Pharmaceuticals Incorporated |
6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
|
EP2428516A1
(en)
|
2003-11-19 |
2012-03-14 |
Metabasis Therapeutics, Inc. |
Novel phosphorus-containing thyromimetics
|
AU2004305075A1
(en)
*
|
2003-12-19 |
2005-07-07 |
The Regents Of The University Of California |
Methods and materials for assessing prostate cancer therapies
|
NZ550102A
(en)
*
|
2004-02-24 |
2010-10-29 |
Univ California |
Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
|
US8519158B2
(en)
*
|
2004-03-12 |
2013-08-27 |
Ligand Pharmaceuticals Incorporated |
Androgen receptor modulator compounds and methods
|
AU2005285035B2
(en)
*
|
2004-09-10 |
2012-03-22 |
Janssen Pharmaceutica N.V. |
Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS)
|
US7709517B2
(en)
|
2005-05-13 |
2010-05-04 |
The Regents Of The University Of California |
Diarylhydantoin compounds
|
KR101332924B1
(ko)
|
2005-05-13 |
2013-11-26 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
디아릴히단토인 화합물
|
BRPI0609191B8
(pt)
*
|
2005-06-17 |
2021-05-25 |
Ligand Pharm Inc |
métodos e compostos moduladores de receptor de androgênio
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
FR2896503B1
(fr)
*
|
2006-01-23 |
2012-07-13 |
Aventis Pharma Sa |
Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
|
HUE027894T2
(en)
|
2006-03-27 |
2016-11-28 |
Univ California |
An androgen receptor modulator for the treatment of prostate cancer and androgen receptor related diseases
|
SG10201408699TA
(en)
*
|
2006-03-29 |
2015-02-27 |
Univ California |
Diarylthiohydantoin compounds
|
CN101663262B
(zh)
|
2006-12-01 |
2014-03-26 |
百时美施贵宝公司 |
用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
|
US9232959B2
(en)
|
2007-01-02 |
2016-01-12 |
Aquabeam, Llc |
Multi fluid tissue resection methods and devices
|
ES2959025T3
(es)
|
2007-01-02 |
2024-02-19 |
Aquabeam Llc |
Dispositivos y procedimientos mínimamente invasivos para el tratamiento de enfermedades de la próstata
|
US20080245375A1
(en)
*
|
2007-04-05 |
2008-10-09 |
Medtronic Vascular, Inc. |
Benign Prostatic Hyperplasia Treatments
|
EP2620432A3
(en)
|
2007-10-26 |
2013-12-18 |
The Regents Of the University of California |
Diarylhydantoin compounds
|
EP2259742B1
(en)
*
|
2008-03-06 |
2020-01-01 |
AquaBeam LLC |
Tissue ablation and cautery with optical energy carried in fluid stream
|
WO2010093601A1
(en)
|
2009-02-10 |
2010-08-19 |
Metabasis Therapeutics, Inc. |
Novel sulfonic acid-containing thyromimetics, and methods for their use
|
WO2014127242A2
(en)
|
2013-02-14 |
2014-08-21 |
Procept Biorobotics Corporation |
Aquablation aquabeam eye surgery methods and apparatus
|
WO2016037137A1
(en)
|
2014-09-05 |
2016-03-10 |
Procept Biorobotics Corporation |
Physician controlled tissue resection integrated with treatment mapping of target organ images
|
US9848904B2
(en)
|
2009-03-06 |
2017-12-26 |
Procept Biorobotics Corporation |
Tissue resection and treatment with shedding pulses
|
FR2944524B1
(fr)
|
2009-04-17 |
2012-11-30 |
Ipsen Pharma Sas |
Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
|
WO2016004071A1
(en)
|
2014-06-30 |
2016-01-07 |
Procept Biorobotics Corporation |
Fluid jet tissue resection and cold coagulation (aquablation) methods and apparatus
|
EP3124481B1
(en)
|
2010-02-16 |
2018-03-28 |
Aragon Pharmaceuticals, Inc. |
Androgen receptor modulators and uses thereof
|
WO2012109387A1
(en)
|
2011-02-08 |
2012-08-16 |
Halozyme, Inc. |
Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
|
EP2819599B1
(en)
|
2012-02-29 |
2018-05-23 |
Procept Biorobotics Corporation |
Automated image-guided tissue resection and treatment
|
SG10201912719TA
(en)
|
2012-09-26 |
2020-02-27 |
Aragon Pharmaceuticals Inc |
Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
|
JOP20200097A1
(ar)
|
2013-01-15 |
2017-06-16 |
Aragon Pharmaceuticals Inc |
معدل مستقبل أندروجين واستخداماته
|
ES2798899T3
(es)
|
2013-02-25 |
2020-12-14 |
Novartis Ag |
Mutación novedosa del receptor de andrógenos
|
CN109965976B
(zh)
|
2013-09-06 |
2022-05-31 |
普罗赛普特生物机器人公司 |
利用致脱脉冲的用于消融组织的装置
|
TWI726969B
(zh)
|
2016-01-11 |
2021-05-11 |
比利時商健生藥品公司 |
用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
|
CA3036011A1
(en)
|
2016-08-20 |
2018-03-01 |
Ftf Pharma Private Limited |
Pharmaceutical composition comprising an androgen receptor inhibitor
|
CN107216290B
(zh)
*
|
2017-06-12 |
2021-03-16 |
陕西科技大学 |
一种3-丁基-5,5-二甲基海因咪唑季铵盐及其制备方法
|
AU2018351714A1
(en)
|
2017-10-16 |
2020-04-30 |
Aragon Pharmaceuticals, Inc. |
Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
|